Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer
Within the framework of China's and the United States' healthcare system, LU-AT is unlikely to represent a cost-effective first-line treatment for ES-SCLC.
Authors
- Leilei Bao (ORCID: https://orcid.org/0000-0003-4403-4598)
- Yufan Huang (ORCID: https://orcid.org/0000-0002-7186-4071)
- Zichun Xu
Institutions
- Second Military Medical University (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.3389/fimmu.2025.1658740
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province